Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs

Toxicology and Applied Pharmacology

Volumn 277, Issue 1, 2014, Pages 30-38

  Hashimoto, Yosuke ^a   Shimizu, Taro ^a   Mima, Yu ^a   Abu Lila, Amr S ^a,b   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Zagazig University   (Egypt)

Author keywords

Accelerated blood clearance phenomenon; Anti PEG IgM; Complement activation; Drug delivery system; Hybridoma; PEGylated products

Indexed keywords

FREUND ADJUVANT; HIK M09 MONOCLONAL ANTIBODY; HIK M11 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN M; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN;

ACCELERATED BLOOD CLEARANCE PHENOMENON; ANTI-PEG IGM; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; HYBRIDOMA; PEGYLATED PRODUCTS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; HYBRIDOMAS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS, WISTAR; SPLEEN;

EID: 84897940686     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.03.002     Document Type: Article

References (33)

1. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
2. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
3. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer Am. Cancer Soc. 2007, 110:103-111.
4. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 1959, 234:469-471.
5. Brinckerhoff L.H., Kalashnikov V.V., Thompson L.W., Yamshchikov G.V., Pierce R.A., Galavotti H.S., Engelhard V.H., Slingluff C.L. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 1999, 83:326-334.
6. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 2003, 55:1261-1277.
7. Chao T.C., Wang W.S., Yen C.C., Chiou T.J., Liu J.H., Chen P.M. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox((R))) in patients with metastatic breast cancer. Cancer Invest. 2003, 21:837-847.
8. Cheng T.L., Wu P.Y., Wu M.F., Chern J.W., Roffler S.R. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 1999, 10:520-528.
9. Cheng T.L., Cheng C.M., Chen B.M., Tsao D.A., Chuang K.H., Hsiao S.W., Lin Y.H., Roffler S.R. Monoclonal antibody-based quantitation of poly(ethylene glycol-derivatized proteins, liposomes, and nanoparticles. Bioconjug. Chem. 2005, 16:1225-1231.
10. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 2003, 55:1293-1302.
11. Harashima H., Yamane C., Kume Y., Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J. Pharmacokinet. Biopharm. 1993, 21:299-308.
12. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
13. Hsiao S.M., Chen C.A., Lin H.H., Hsieh C.Y., Wei L.H. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox (R)) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol. Oncol. 2009, 112:35-39.
14. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
15. Kaminskas L.M., Mcleod V.M., Porter C.J.H., Boyd B.J. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci. U.S. 2011, 100:5069-5077.
16. Kingshott P., Thissen H., Griesser H.J. Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. Biomaterials 2002, 23:2043-2056.
17. Liu Y.J., Reidler H., Pan J., Milunic D., Qin D.J., Chen D., Vallejo Y.R., Yin R. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J. Pharmacol. Toxicol. Methods 2011, 64:238-245.
18. Matthews S.J., McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin. Ther. 2004, 26:991-1025.
19. Moody M.A., Haynes B.F. Antigen-specific B cell detection reagents: use and quality control. Cytometry A 2008, 73A:1086-1092.
20. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 2012, 161:461-472.
21. Reid K.B., Porter R.R. The proteolytic activation systems of complement. Annu. Rev. Biochem. 1981, 50:433-464.
22. Richter A.W., Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 1983, 70:124-131.
23. Roberts M.J., Bentley M.D., Harris J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 2002, 54:459-476.
24. Saadati R., Dadashzadeh S., Abbasian Z., Soleimanjahi H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm. Res. 2013, 30:985-995.
25. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O., Hanauer S.B., McColm J., Bloomfield R., Sandborn W.J. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 2007, 357:239-250.
26. Sherman M.R., Saifer M.G.P., Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 2008, 60:59-68.
27. Sherman M.R., Williams L.D., Sobczyk M.A., Michaels S.J., Saifer M.G.P. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 2012, 23:485-499.
28. Su Y.C., Chen B.M., Chuang K.H., Cheng T.L., Roffler S.R. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug. Chem. 2010, 21:1264-1270.
29. Sun X., Yang Z., Li S., Tan Y., Zhang N., Wang X., Yagi S., Yoshioka T., Takimoto A., Mitsushima K., Suginaka A., Frenkel E.P., Hoffman R.M. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation. Cancer Res. 2003, 63:8377-8383.
30. Tagami T., Uehara Y., Moriyoshi N., Ishida T., Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 2011, 151:149-154.
31. Uziely B., Jeffers S., Isacson R., Kutsch K., Weitsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal doxorubicin - antitumor-activity and unique toxicities during 2 complementary phase-I studies. J. Clin. Oncol. 1995, 13:1777-1785.
32. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
33. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 2007, 119:236-244.